Abstract 416P
Background
With the increasing availability of new therapies and the absence of reliable biomarkers for ET, determining the 2L Tx algorithm for luminal-like (HRpos) mBC has become more challenging. This study aimed to assess the impact of LB biomarkers at the diagnosis of metastatic relapse before first line (1L) ET on 2L progression free survival (PFS2) and overall survival (OS2).
Methods
The prospective multicenter MAGNETIC.1 trial (NCT05814224) enrolled 148 patients (pts) with HRpos mBC treated with 1L ET and longitudinally characterized through LB. The prognostic impact of clinical and LB features was evaluated using Cox regression analysis. Survival estimates were generated using the Kaplan-Meier method.
Results
Overall, 88 pts (59%) experienced disease progression (PD) to 1L. 2L Tx options were chemotherapy (CT) (53%), CDK4/6i beyond PD (20%), ET alone (15%), ET + everolimus (8%), and ET + alpelisib (1%). The main baseline (BL) metastatic (mts) sites were bone (73%) and lymph nodes (55%), while new mts sites at PD included liver (44%), bone (19%) and lung (8%). LB biomarkers significantly associated with PFS2 were BL methylation of ESR1 promoter A (PromA) and promoter B (PromB) dichotomized at 75th percentile (high versus low) (respectively P=0.05 and P=0.022), PromA at 6 months (T5) (P=0.013), and BL Actin short (As) fragments (P=0.007). The latter was confirmed after correction for 2L Tx type (CT versus ET) and 1L progression free survival (PFS1) (P=0.007). PromA dynamics was also prognostic, regardless of BL Prom A (P=0.013). No impact of clinical features emerged for PFS2. Liver mts, 2L Tx type, BL As, BL AKT1 and BL ERBB2 mutational status were prognostic for OS2. Significance was confirmed at multivariable analysis corrected for PFS1 for BL As (P=<0.001), BL AKT1 (P=0.001) and BL ERBB2 (P=0.003).
Conclusions
LB biomarkers at relapse exhibit prognostic significance not only for 1L but also for 2L Tx, independently of main clinical features. Characterization through plasma As fragments may offer insights into both PFS2 and OS2, potentially guiding Tx sequencing beyond the 1L.
Clinical trial identification
NCT05814224. Release date: not applicable.
Editorial acknowledgement
Legal entity responsible for the study
Centro di Riferimento Oncologico (CRO), IRCCS - Aviano (PN), Italy.
Funding
Italian Ministry of Health (Ricerca finalizzata).
Disclosure
S. Spazzapan: Financial Interests, Personal, Advisory Board: AstraZeneca, Daiichi Sankyo, MSD, Novartis, Pfizer, Seagen, Mundipharma; Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Daiichi Sankyo, MSD, Novartis, Pfizer, Seagen, Mundipharma; Financial Interests, Personal, Research Grant: AstraZeneca, Daiichi Sankyo, MSD, Novartis, Pfizer, Seagen, Mundipharma. A.M.M. Minisini: Financial Interests, Personal, Advisory Board: Novartis, MSD, BMS, Merck, PierreFabre, Gilead, Seagen; Financial Interests, Personal, Speaker, Consultant, Advisor: Novartis, MSD, BMS, Merck, Sunpharma, Sanofi, PierreFabre; Financial Interests, Personal, Other: MSD, AstraZeneca, Pharmamar, GSK; Financial Interests, Personal, Advisory Role: Sunpharma; Financial Interests, Personal, Other, Travel grant: PierreFabre, Gilead. L. Gerratana: Financial Interests, Personal, Advisory Board: AstraZeneca, Daiichi Sankyo, Eli Lilly, GSK, Incyte, Novartis, Pfizer, Merck Sharp & Dohme, Menarini Stemline, Abbvie; Financial Interests, Personal and Institutional, Research Funding: Menarini Silicon Biosystems; Financial Interests, Personal, Other, Travel expenses: Menarini Stemline. F. Puglisi: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Daiichi Sankyo, Celgene, Eisai, Eli Lilly, Exact Sciences, Gilead, Ipsen, Italfarmaco, Menarini, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Seagen, Takeda, Viatris; Financial Interests, Personal and Institutional, Research Funding: Astrazeneca, Eisai, Roche; Financial Interests, Personal, Invited Speaker: Amgen, AstraZeneca, Daiichi Sankyo, Celgene, Eli Lilly, Exact Sciences, Gilead, Ipsen, Italfarmaco, Menarini, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Seagen, Takeda, Viatris; Financial Interests, Personal, Other, Travel grant: Amgen, AstraZeneca, Daiichi Sankyo, Celgene, Eisai, Eli Lilly, Exact Sciences, Gilead, Ipsen, Italfarmaco, Menarini, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Seagen, Takeda, Viatris; Financial Interests, Personal, Research Grant: Amgen, AstraZeneca, Daiichi Sankyo, Celgene, Eisai, Eli Lilly, Exact Sciences, Gilead, Ipsen, Italfarmaco, Menarini, MSD, Novartis, Pierre Fabre, Pfizer, Seagen, Takeda, Viatris; Financial Interests, Personal, Speaker, Consultant, Advisor: Eisai ; Financial Interests, Personal, Research Funding: Roche. All other authors have declared no conflicts of interest.
Resources from the same session
533P - First-line treatment in older patients with metastatic colorectal cancer: A large real-world study
Presenter: debora basile
Session: Poster session 15
534P - Second-line treatment in older patients with metastatic colorectal cancer: The ELECTRA study
Presenter: Alessia Cordua
Session: Poster session 15
535P - Safety and efficacy of first-line immune checkpoint inhibitors in elderly colorectal cancer patients: An Italian real-world multicenter experience
Presenter: Alessandra Boccaccino
Session: Poster session 15
536P - A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone for liver metastasis from colorectal cancer: Long-term results of JCOG0603
Presenter: Yukihide Kanemitsu
Session: Poster session 15
537P - Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Updated findings from a single-arm, prospective phase II trial (RIFLE)
Presenter: Yajiie Chen
Session: Poster session 15
538P - Combined hepatectomy with complete cytoreduction (CCS) and hyperthermic intraperitoneal chemotherapy (HIPEC) vs. HIPEC alone for metastatic colorectal cancer: A systematic review and meta-analysis
Presenter: Gabriele Lech
Session: Poster session 15
540P - Early treatment discontinuation (ETD) in dMMR/MSI-H metastastic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs)
Presenter: Julien Taieb
Session: Poster session 15
541P - Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Subgroup efficacy and expanded safety analyses from CheckMate 8HW
Presenter: Thierry André
Session: Poster session 15